Eargo is a medical device company on a mission to improve hearing health. Our innovative products and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. We believe our Eargo hearing aids are the first virtually invisible, rechargeable, completely-in-canal, FDA-regulated devices indicated to compensate for mild to moderate hearing loss. Our differentiated, consumer-first approach empowers consumers to take control of their hearing. Consumers can purchase online, at retail locations or over the phone and get personalized and convenient consultation and support from hearing professionals via phone, text, email or video chat. Eargo hearing aids are offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels in the United States.
Company profile
Ticker
EAR
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Avanos Medical • Edwards Lifesciences • Invacare • MSA Safety • Align Technology • Surgalign ...
SEC CIK
Corporate docs
Subsidiaries
Eargo Hearing, Inc. • Eargo Screening, LLC ...
IRS number
273879804
EAR stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
13 Feb 23
424B3
Prospectus supplement
13 Feb 23
EFFECT
Notice of effectiveness
13 Feb 23
CORRESP
Correspondence with SEC
9 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Feb 23
S-1/A
IPO registration (amended)
30 Jan 23
CORRESP
Correspondence with SEC
30 Jan 23
8-K
Material Modifications to Rights of Security Holders
17 Jan 23
8-K
Entry into a Material Definitive Agreement
13 Jan 23
8-K
Eargo to Complete a 1-for-20 Reverse Stock Split
11 Jan 23
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 88.08 mm | 88.08 mm | 88.08 mm | 88.08 mm | 88.08 mm | 88.08 mm |
| Cash burn (monthly) | 6.19 mm | 5.70 mm | 16.88 mm | 13.27 mm | 4.66 mm | 11.82 mm |
| Cash used (since last report) | 35.35 mm | 32.57 mm | 96.46 mm | 75.84 mm | 26.64 mm | 67.55 mm |
| Cash remaining | 52.72 mm | 55.51 mm | -8.39 mm | 12.24 mm | 61.44 mm | 20.52 mm |
| Runway (months of cash) | 8.5 | 9.7 | -0.5 | 0.9 | 13.2 | 1.7 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 45 |
| Opened positions | 12 |
| Closed positions | 19 |
| Increased positions | 17 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 193.28 bn |
| Total shares | 667.28 mm |
| Total puts | 298.00 k |
| Total calls | 57.40 k |
| Total put/call ratio | 5.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Patient Square Capital | 316.43 mm | $181.94 bn |
| PSC Echo | 316.43 mm | $0.00 |
| BLK Blackrock | 6.09 mm | $3.50 bn |
| NEA Management | 4.52 mm | $2.60 bn |
| New Enterprise Associates 15 | 4.52 mm | $150.07 mm |
| Oasis Management | 3.11 mm | $1.79 bn |
| Nan Fung | 2.96 mm | $1.70 bn |
| Geode Capital Management | 1.97 mm | $1.13 mm |
| Alger Associates | 1.96 mm | $39.15 mm |
| Longitude Capital Partners IV | 1.92 mm | $64.33 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Feb 23 | Christian Gormsen | Common Stock | Sell | Dispose S | No | No | 7.3701 | 64 | 471.69 | 6,123 |
| 17 Feb 23 | Mark Thorpe | Common Stock | Sell | Dispose S | No | No | 7.4201 | 4 | 29.68 | 1,070 |
| 17 Feb 23 | Adam Laponis | Common Stock | Sell | Dispose S | No | No | 7.3701 | 21 | 154.77 | 3,190 |
| 17 Feb 23 | William Brownie | Common Stock | Sell | Dispose S | No | No | 7.3701 | 15 | 110.55 | 8,307 |
| 1 Feb 23 | Christian Gormsen | Stock Option Common Stock | Grant | Acquire A | No | No | 11.58 | 325,000 | 3.76 mm | 325,000 |
| 1 Feb 23 | Christian Gormsen | Stock Option Common Stock | Grant | Acquire A | No | No | 11.58 | 325,000 | 3.76 mm | 325,000 |
Press releases
Eargo to Report Fourth Quarter 2022 Financial Results on March 23, 2023
17 Mar 23
Nasdaq Confirms Eargo's Minimum Bid Price Deficiency is Cured
6 Feb 23
Eargo Effects 1-for-20 Reverse Stock Split
17 Jan 23
Hearing Wellness Pioneer Eargo Launches Eargo 7, Its Most Revolutionary Device Yet, at CES
4 Jan 23